76
|
Zhang Y, Wang K, Yu H, Zhao T, Lin L, Qin X, Wu T, Chen D, Hu Y, Wu Y. Incidence and characteristics of aspiration pneumonia in adults in Beijing, China, 2011-2017. Public Health 2023; 220:65-71. [PMID: 37270854 DOI: 10.1016/j.puhe.2023.04.021] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2022] [Revised: 04/21/2023] [Accepted: 04/26/2023] [Indexed: 06/06/2023]
Abstract
OBJECTIVES This study aimed to estimate aspiration pneumonia (AP) incidence and describe comorbid characteristics and mortality in Beijing, China. STUDY DESIGN A historical cohort study was conducted based on medical claim records. METHODS Patients admitted with a primary diagnosis of AP were identified from approximately 12 million adults who enrolled in the Urban Employee Basic Medical Insurance program in Beijing, China, from January 2011 to December 2017. The incidences of AP and pneumonia with risk factors for aspiration (PRFA) were estimated by a Poisson distribution. The estimated annual percentage change was reported to represent the average percentage change in incidence per year. Characteristics and 6-month and 1-year all-cause mortality rates for AP and suspected AP patients were described and compared with community-acquired pneumonia (CAP). RESULTS The incidence rates of hospitalized AP and PRFA were 9.4 (95% confidence interval [CI]: 7.6, 11.3) and 102.9 (95% CI: 95.8, 110.3) per 100,000 person-years, respectively. The incidences increased rapidly with age and were stable across the observed years. Patients with AP and PRFA possessed a greater burden of comorbidities than CAP (mean age-adjusted Charlson comorbidity indices for AP: 7.72, PRFA: 7.83, and CAP: 2.84). The 6-month and 1-year all-cause mortality rates for those with AP and PRFA were higher than those for patients with CAP (6-month mortality, AP: 35.2%, PRFA: 21.8%, CAP: 11.1%; 1-year mortality, AP: 42.7%, PRFA: 26.6%, CAP: 13.2%). CONCLUSIONS The incidence of AP and PRFA in Beijing was reported, presenting a full picture of the disease burden. The results provide baseline information for AP prevention.
Collapse
|
77
|
Ablikim M, Achasov MN, Adlarson P, Aliberti R, Amoroso A, An MR, An Q, Bai Y, Bakina O, Balossino I, Ban Y, Batozskaya V, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bianco E, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang TT, Chang WL, Che GR, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen YQ, Chen ZJ, Cheng WS, Choi SK, Chu X, Cibinetto G, Coen SC, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding B, Ding XX, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Duan ZH, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Fu YW, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Gramigna S, Greco M, Gu MH, Gu YT, Guan CY, Guan ZL, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, H XT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Holtmann T, Hong PC, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang XT, Huang YP, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Jeong JH, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia ZK, Jiang PC, Jiang SS, Jiang TJ, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, K X, Kabana S, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Khoukaz A, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei TT, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li HB, Li HJ, Li HN, Li H, Li JR, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Li YG, Li ZJ, Li ZX, Li ZY, Liang C, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin DX, Lin T, Liu BJ, Liu BX, Liu C, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu LC, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma JL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pei YP, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Plura S, Pogodin S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Salone N, Sarantsev A, Schelhaas Y, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen WH, Shen XY, Shi BA, Shi HC, Shi JY, Shi QQ, Shi RS, Shi X, Song JJ, Song TZ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su YJ, Sun GB, Sun GX, Sun H, Sun HK, Sun JF, Sun K, Sun L, Sun SS, Sun T, Sun WY, Sun Y, Sun YJ, Sun YZ, Sun ZT, Tan YX, Tang CJ, Tang GY, Tang J, Tang YA, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian WH, Tian Y, Tian ZF, Uman I, Wang B, Wang BL, Wang B, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang M, Wang S, Wang S, Wang T, Wang TJ, Wang W, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XJ, Wang XL, Wang Y, Wang YD, Wang YF, Wang YH, Wang YN, Wang YQ, Wang Y, Wang Y, Wang Z, Wang ZL, Wang ZY, Wang Z, Wei D, Wei DH, Weidner F, Wen SP, Wenzel CW, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu C, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YJ, Wu Z, Xia L, Xian XM, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu WL, Xu XP, Xu YC, Xu ZP, Yan F, Yan L, Yan WB, Yan WC, Yan XQ, Yang HJ, Yang HL, Yang HX, Yang T, Yang Y, Yang YF, Yang YX, Yang Y, Yang ZW, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu T, Yu XD, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zeng YJ, Zhai XY, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HQ, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZL, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu L, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou JH, Zu J. Precision Measurement of the Decay Σ^{+}→pγ in the Process J/ψ→Σ^{+}Σ[over ¯]^{-}. PHYSICAL REVIEW LETTERS 2023; 130:211901. [PMID: 37295102 DOI: 10.1103/physrevlett.130.211901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 02/27/2023] [Revised: 03/29/2023] [Accepted: 05/08/2023] [Indexed: 06/12/2023]
Abstract
Using (10 087±44)×10^{6} J/ψ events collected with the BESIII detector, the radiative hyperon decay Σ^{+}→pγ is studied at an electron-positron collider experiment for the first time. The absolute branching fraction is measured to be (0.996±0.021_{stat}±0.018_{syst})×10^{-3}, which is lower than its world average value by 4.2 standard deviations. Its decay asymmetry parameter is determined to be -0.652±0.056_{stat}±0.020_{syst}. The branching fraction and decay asymmetry parameter are the most precise to date, and the accuracies are improved by 78% and 34%, respectively.
Collapse
|
78
|
Aboona BE, Adam J, Adams JR, Agakishiev G, Aggarwal I, Aggarwal MM, Ahammed Z, Aitbaev A, Alekseev I, Anderson DM, Aparin A, Atchison J, Averichev GS, Bairathi V, Baker W, Ball Cap JG, Barish K, Bhagat P, Bhasin A, Bhatta S, Bordyuzhin IG, Brandenburg JD, Brandin AV, Cai XZ, Caines H, Calderón de la Barca Sánchez M, Cebra D, Ceska J, Chakaberia I, Chan BK, Chang Z, Chen D, Chen J, Chen JH, Chen Z, Cheng J, Cheng Y, Choudhury S, Christie W, Chu X, Crawford HJ, Dale-Gau G, Das A, Daugherity M, Dedovich TG, Deppner IM, Derevschikov AA, Dhamija A, Di Carlo L, Didenko L, Dixit P, Dong X, Drachenberg JL, Duckworth E, Dunlop JC, Engelage J, Eppley G, Esumi S, Evdokimov O, Ewigleben A, Eyser O, Fatemi R, Fazio S, Feng CJ, Feng Y, Finch E, Fisyak Y, Flor FA, Fu C, Geurts F, Ghimire N, Gibson A, Gopal K, Gou X, Grosnick D, Gupta A, Hamed A, Han Y, Harasty MD, Harris JW, Harrison H, He W, He XH, He Y, Hu C, Hu Q, Hu Y, Huang H, Huang HZ, Huang SL, Huang T, Huang X, Huang Y, Huang Y, Humanic TJ, Isenhower D, Isshiki M, Jacobs WW, Jalotra A, Jena C, Ji Y, Jia J, Jin C, Ju X, Judd EG, Kabana S, Kabir ML, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Kelsey M, Kimelman B, Kiselev A, Knospe AG, Ko HS, Kochenda L, Korobitsin AA, Kravtsov P, Kumar L, Kumar S, Kunnawalkam Elayavalli R, Lacey R, Landgraf JM, Lebedev A, Lednicky R, Lee JH, Leung YH, Lewis N, Li C, Li C, Li W, Li X, Li Y, Li Y, Li Z, Liang X, Liang Y, Lin T, Liu C, Liu F, Liu H, Liu H, Liu L, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Lomicky O, Longacre RS, Loyd E, Lu T, Lukow NS, Luo XF, Luong VB, Ma L, Ma R, Ma YG, Magdy N, Mallick D, Margetis S, Matis HS, Mazer JA, McNamara G, Mi K, Minaev NG, Mohanty B, Mooney I, Morozov DA, Mudrokh A, Nagy MI, Nain AS, Nam JD, Nasim M, Neff D, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nishitani R, Nogach LV, Nonaka T, Nunes AS, Odyniec G, Ogawa A, Oh S, Okorokov VA, Okubo K, Page BS, Pak R, Pan J, Pandav A, Pandey AK, Panebratsev Y, Pani T, Parfenov P, Paul A, Perkins C, Pokhrel BR, Posik M, Protzman T, Pruthi NK, Putschke J, Qin Z, Qiu H, Quintero A, Racz C, Radhakrishnan SK, Raha N, Ray RL, Ritter HG, Robertson CW, Rogachevsky OV, Rosales Aguilar MA, Roy D, Ruan L, Sahoo AK, Sahoo NR, Sako H, Salur S, Samigullin E, Sato S, Schmidke WB, Schmitz N, Seger J, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao M, Shao T, Sharma M, Sharma N, Sharma R, Sharma SR, Sheikh AI, Shen DY, Shen K, Shi SS, Shi Y, Shou QY, Si F, Singh J, Singha S, Sinha P, Skoby MJ, Söhngen Y, Song Y, Srivastava B, Stanislaus TDS, Stewart DJ, Strikhanov M, Stringfellow B, Su Y, Sun C, Sun X, Sun Y, Sun Y, Surrow B, Svirida DN, Sweger ZW, Tamis A, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Thomas JH, Tlusty D, Todoroki T, Tokarev MV, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tsai OD, Tsang CY, Tu Z, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vasiliev AN, Verkest V, Videbæk F, Vokal S, Voloshin SA, Wang F, Wang G, Wang JS, Wang X, Wang Y, Wang Y, Wang Y, Wang Z, Webb JC, Weidenkaff PC, Westfall GD, Wieman H, Wilks G, Wissink SW, Wu J, Wu J, Wu X, Wu Y, Xi B, Xiao ZG, Xie W, Xu H, Xu N, Xu QH, Xu Y, Xu Y, Xu Z, Xu Z, Yan G, Yan Z, Yang C, Yang Q, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yu Y, Zha W, Zhang C, Zhang D, Zhang J, Zhang S, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang ZJ, Zhang Z, Zhang Z, Zhao F, Zhao J, Zhao M, Zhou C, Zhou J, Zhou S, Zhou Y, Zhu X, Zurek M, Zyzak M. Observation of Directed Flow of Hypernuclei _{Λ}^{3}H and _{Λ}^{4}H in sqrt[s_{NN}]=3 GeV Au+Au Collisions at RHIC. PHYSICAL REVIEW LETTERS 2023; 130:212301. [PMID: 37295104 DOI: 10.1103/physrevlett.130.212301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/30/2022] [Revised: 01/24/2023] [Accepted: 03/02/2023] [Indexed: 06/12/2023]
Abstract
We report here the first observation of directed flow (v_{1}) of the hypernuclei _{Λ}^{3}H and _{Λ}^{4}H in mid-central Au+Au collisions at sqrt[s_{NN}]=3 GeV at RHIC. These data are taken as part of the beam energy scan program carried out by the STAR experiment. From 165×10^{6} events in 5%-40% centrality, about 8400 _{Λ}^{3}H and 5200 _{Λ}^{4}H candidates are reconstructed through two- and three-body decay channels. We observe that these hypernuclei exhibit significant directed flow. Comparing to that of light nuclei, it is found that the midrapidity v_{1} slopes of _{Λ}^{3}H and _{Λ}^{4}H follow baryon number scaling, implying that the coalescence is the dominant mechanism for these hypernuclei production in the 3 GeV Au+Au collisions.
Collapse
|
79
|
Wang Y, Li F, Hu Y, Sun Y, Tian C, Cao Y, Wang W, Feng W, Yan J, Wei J, Du X, Wang H. Clinical outcomes of intra-arterial chemotherapy combined with iodine-125 seed brachytherapy in the treatment of malignant superior vena cava syndrome caused by small cell lung cancer. Cancer Radiother 2023:S1278-3218(23)00068-9. [PMID: 37230904 DOI: 10.1016/j.canrad.2023.01.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/13/2022] [Revised: 12/29/2022] [Accepted: 01/14/2023] [Indexed: 05/27/2023]
Abstract
PURPOSE Currently there is a lack of effective treatment strategies for malignant superior vena cava syndrome (SVCS). We aim to investigate the therapeutic effect of intra-arterial chemotherapy (IAC) combined with the Single Needle Cone Puncture method for the 125I brachytherapy (SNCP-125I) in treating SVCS caused by stage III/IV Small Cell Lung Cancer (SCLC). MATERIALS AND METHODS Sixty-two patients with SCLC who developed SVCS from January 2014 to October 2020 were investigated in this study. Out of these 62 patients, 32 underwent IAC combined with SNCP-125I (Group A) and 30 patients received IAC treatment only (Group B). Clinical symptom remission, response rate, disease control rate, and overall survival of these two groups of patients were analyzed and compared. RESULTS The remission rate of symptoms including dyspnea, edema, dysphagia, pectoralgia, and cough of malignant SVCS in Group A was significantly higher than that in Group B (70.5 and 50.53%, P=0.0004, respectively). The disease control rates (DCR, PR+CR+SD) of Group A and B were 87.5 and 66.7%, respectively (P=0.049). Response rates (RR, PR+CR) of Group A and Group B were 71.9 and 40% (P=0.011). The median overall survival (OS) of Group A was significantly longer than that in Group B which was 18 months compared to 11.75 months (P=0.0360). CONCLUSIONS IAC treatment effectively treated malignant SVCS in advanced SCLC patients. IAC combined with SNCP-125I in the treatment of malignant SVCS caused by SCLC showed improved clinical outcomes including symptom remission and local tumor control rates than IAC treatment only in treating SCLC-induced malignant SVCS.
Collapse
|
80
|
Abdulhamid MI, Aboona BE, Adam J, Adams JR, Agakishiev G, Aggarwal I, Aggarwal MM, Ahammed Z, Aitbaev A, Alekseev I, Anderson DM, Aparin A, Aslam S, Atchison J, Averichev GS, Bairathi V, Baker W, Ball Cap JG, Barish K, Bhagat P, Bhasin A, Bhatta S, Bordyuzhin IG, Brandenburg JD, Brandin AV, Cai XZ, Caines H, Calderón de la Barca Sánchez M, Cebra D, Ceska J, Chakaberia I, Chan BK, Chang Z, Chatterjee A, Chen D, Chen J, Chen JH, Chen Z, Cheng J, Cheng Y, Choudhury S, Christie W, Chu X, Crawford HJ, Dale-Gau G, Das A, Daugherity M, Dedovich TG, Deppner IM, Derevschikov AA, Dhamija A, Di Carlo L, Didenko L, Dixit P, Dong X, Drachenberg JL, Duckworth E, Dunlop JC, Engelage J, Eppley G, Esumi S, Evdokimov O, Ewigleben A, Eyser O, Fatemi R, Fazio S, Feng CJ, Feng Y, Finch E, Fisyak Y, Flor FA, Fu C, Geurts F, Ghimire N, Gibson A, Gopal K, Gou X, Grosnick D, Gupta A, Hamed A, Han Y, Harasty MD, Harris JW, Harrison-Smith H, He W, He XH, He Y, Hu C, Hu Q, Hu Y, Huang H, Huang HZ, Huang SL, Huang T, Huang X, Huang Y, Huang Y, Humanic TJ, Isenhower D, Isshiki M, Jacobs WW, Jalotra A, Jena C, Ji Y, Jia J, Jin C, Ju X, Judd EG, Kabana S, Kabir ML, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kechechyan A, Kelsey M, Kimelman B, Kiselev A, Knospe AG, Ko HS, Kochenda L, Korobitsin AA, Kravtsov P, Kumar L, Kumar S, Kunnawalkam Elayavalli R, Lacey R, Landgraf JM, Lebedev A, Lednicky R, Lee JH, Leung YH, Lewis N, Li C, Li W, Li X, Li Y, Li Y, Li Z, Liang X, Liang Y, Lin T, Liu C, Liu F, Liu H, Liu H, Liu L, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Lomicky O, Longacre RS, Loyd EM, Lu T, Lukow NS, Luo XF, Luong VB, Ma L, Ma R, Ma YG, Magdy N, Mallick D, Margetis S, Matis HS, Mazer JA, McNamara G, Mi K, Minaev NG, Mohanty B, Mondal MM, Mooney I, Morozov DA, Mudrokh A, Nagy MI, Nain AS, Nam JD, Nasim M, Neff D, Nelson JM, Nemes DB, Nie M, Nigmatkulov G, Niida T, Nishitani R, Nogach LV, Nonaka T, Odyniec G, Ogawa A, Oh S, Okorokov VA, Okubo K, Page BS, Pak R, Pan J, Pandav A, Pandey AK, Panebratsev Y, Pani T, Parfenov P, Paul A, Perkins C, Pokhrel BR, Posik M, Protzman T, Pruthi NK, Putschke J, Qin Z, Qiu H, Quintero A, Racz C, Radhakrishnan SK, Raha N, Ray RL, Ritter HG, Robertson CW, Rogachevsky OV, Rosales Aguilar MA, Roy D, Ruan L, Sahoo AK, Sahoo NR, Sako H, Salur S, Samigullin E, Sato S, Schmidke WB, Schmitz N, Seger J, Seto R, Seyboth P, Shah N, Shahaliev E, Shanmuganathan PV, Shao T, Sharma M, Sharma N, Sharma R, Sharma SR, Sheikh AI, Shen DY, Shen K, Shi SS, Shi Y, Shou QY, Si F, Singh J, Singha S, Sinha P, Skoby MJ, Söhngen Y, Song Y, Srivastava B, Stanislaus TDS, Stewart DJ, Strikhanov M, Stringfellow B, Su Y, Sun C, Sun X, Sun Y, Sun Y, Surrow B, Svirida DN, Sweger ZW, Tamis A, Tang AH, Tang Z, Taranenko A, Tarnowsky T, Thomas JH, Tlusty D, Todoroki T, Tokarev MV, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Tsai OD, Tsang CY, Tu Z, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vasiliev AN, Verkest V, Videbæk F, Vokal S, Voloshin SA, Wang F, Wang G, Wang JS, Wang X, Wang Y, Wang Y, Wang Y, Wang Z, Webb JC, Weidenkaff PC, Westfall GD, Wieman H, Wilks G, Wissink SW, Wu J, Wu J, Wu X, Wu Y, Xi B, Xiao ZG, Xie G, Xie W, Xu H, Xu N, Xu QH, Xu Y, Xu Y, Xu Z, Xu Z, Yan G, Yan Z, Yang C, Yang Q, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yu N, Yu Y, Zha W, Zhang C, Zhang D, Zhang J, Zhang S, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang ZJ, Zhang Z, Zhang Z, Zhao F, Zhao J, Zhao M, Zhou C, Zhou J, Zhou S, Zhou Y, Zhu X, Zurek M, Zyzak M. Beam Energy Dependence of Triton Production and Yield Ratio (N_{t}×N_{p}/N_{d}^{2}) in Au+Au Collisions at RHIC. PHYSICAL REVIEW LETTERS 2023; 130:202301. [PMID: 37267557 DOI: 10.1103/physrevlett.130.202301] [Citation(s) in RCA: 1] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 09/20/2022] [Revised: 02/21/2023] [Accepted: 03/30/2023] [Indexed: 06/04/2023]
Abstract
We report the triton (t) production in midrapidity (|y|<0.5) Au+Au collisions at sqrt[s_{NN}]=7.7-200 GeV measured by the STAR experiment from the first phase of the beam energy scan at the Relativistic Heavy Ion Collider. The nuclear compound yield ratio (N_{t}×N_{p}/N_{d}^{2}), which is predicted to be sensitive to the fluctuation of local neutron density, is observed to decrease monotonically with increasing charged-particle multiplicity (dN_{ch}/dη) and follows a scaling behavior. The dN_{ch}/dη dependence of the yield ratio is compared to calculations from coalescence and thermal models. Enhancements in the yield ratios relative to the coalescence baseline are observed in the 0%-10% most central collisions at 19.6 and 27 GeV, with a significance of 2.3σ and 3.4σ, respectively, giving a combined significance of 4.1σ. The enhancements are not observed in peripheral collisions or model calculations without critical fluctuation, and decreases with a smaller p_{T} acceptance. The physics implications of these results on the QCD phase structure and the production mechanism of light nuclei in heavy-ion collisions are discussed.
Collapse
|
81
|
Roddie C, Lekakis LJ, Marzolini MAV, Ramakrishnan A, Zhang Y, Hu Y, Peddareddigari VGR, Khokhar N, Chen R, Basilico S, Raymond M, Vargas FA, Duffy K, Brugger W, O’Reilly MA, Wood L, Linch DC, Peggs KS, Bachier C, Budde EL, Lee Batlevi C, Bartlett N, Irvine D, Tholouli E, Osborne W, Ardeshna KM, Pule MA. Dual targeting of CD19 and CD22 with bicistronic CAR-T cells in patients with relapsed/refractory large B-cell lymphoma. Blood 2023; 141:2470-2482. [PMID: 36821767 PMCID: PMC10646794 DOI: 10.1182/blood.2022018598] [Citation(s) in RCA: 5] [Impact Index Per Article: 5.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/11/2022] [Revised: 01/13/2023] [Accepted: 02/09/2023] [Indexed: 02/25/2023] Open
Abstract
Relapse after CD19-directed chimeric antigen receptor T-cell (CAR-T) therapy for large B-cell lymphoma (LBCL) is commonly ascribed to antigen loss or CAR-T exhaustion. Multiantigen targeting and programmed cell death protein-1 blockade are rational approaches to prevent relapse. Here, we test CD19/22 dual-targeting CAR-T (AUTO3) plus pembrolizumab in relapsed/refractory LBCL (NCT03289455). End points include toxicity (primary) and response rates (secondary). Fifty-two patients received AUTO3 and 48/52 received pembrolizumab. Median age was 59 years (range, 27-83), 46/52 had stage III/ IV disease and median follow-up was 21.6 months. AUTO3 was safe; grade 1-2 and grade 3 cytokine release syndrome affected 18/52 (34.6%) and 1/52 (1.9%) patients, neurotoxicity arose in 4 patients (2/4, grade 3-4), and hemophagocytic lymphohistiocytosis affected 2 patients. Outpatient administration was tested in 20 patients, saving a median of 14 hospital days per patient. Overall response rates were 66% (48.9%, complete response [CR]; 17%, partial response). Median duration of remission (DOR) for CR patients was not reached and for all responding patients was 8.3 months (95% confidence interval [CI]: 3.0-not evaluable). 54.4% (CI: 32.8-71.7) of CR patients and 42.6% of all responding patients were projected to remain progression-free at ≥12 months. AUTO3 ± pembrolizumab for relapsed/refractory LBCL was safe and delivered durable remissions in 54.4% of complete responders, associated with robust CAR-T expansion. Neither dual-targeting CAR-T nor pembrolizumab prevented relapse in a significant proportion of patients, and future developments include next-generation-AUTO3, engineered for superior expansion in vivo, and selection of CAR binders active at low antigen densities.
Collapse
|
82
|
Ablikim M, Achasov MN, Adlarson P, Aliberti R, Amoroso A, An MR, An Q, Bai Y, Bakina O, Balossino I, Ban Y, Batozskaya V, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bianco E, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang TT, Chang WL, Che GR, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen YQ, Chen ZJ, Cheng WS, Choi SK, Chu X, Cibinetto G, Coen SC, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding B, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Duan ZH, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Fu YW, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Gramigna S, Greco M, Gu MH, Gu YT, Guan CY, Guan ZL, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, H XT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Holtmann T, Hong PC, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang XT, Huang YP, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Jeong JH, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia ZK, Jiang PC, Jiang SS, Jiang TJ, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, K X, Kabana S, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Khoukaz A, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei TT, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li HB, Li HJ, Li HN, Li H, Li JR, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Li YG, Li ZJ, Li ZX, Li ZY, Liang C, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin DX, Lin T, Liu BX, Liu BJ, Liu C, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu LC, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma JL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pei YP, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Plura S, Pogodin S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Sarantsev A, Schelhaas Y, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen WH, Shen XY, Shi BA, Shi HC, Shi JY, Shi QQ, Shi RS, Shi X, Song JJ, Song TZ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su YJ, Sun GB, Sun GX, Sun H, Sun HK, Sun JF, Sun K, Sun L, Sun SS, Sun T, Sun WY, Sun Y, Sun YJ, Sun YZ, Sun ZT, Tan YX, Tang CJ, Tang GY, Tang J, Tang YA, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian WH, Tian Y, Tian ZF, Uman I, Wang B, Wang BL, Wang B, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang M, Wang S, Wang T, Wang TJ, Wang W, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XJ, Wang XL, Wang Y, Wang YD, Wang YF, Wang YH, Wang YN, Wang YQ, Wang Y, Wang Y, Wang Z, Wang ZL, Wang ZY, Wang Z, Wei D, Wei DH, Weidner F, Wen SP, Wenzel CW, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu C, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YJ, Wu Z, Xia L, Xian XM, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu WL, Xu XP, Xu YC, Xu ZP, Yan F, Yan L, Yan WB, Yan WC, Yan XQ, Yang HJ, Yang HL, Yang HX, Yang T, Yang Y, Yang YF, Yang YX, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu T, Yu XD, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zeng YJ, Zhai XY, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HQ, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZL, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu L, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou JH, Zu J. Measurements of the Electric and Magnetic Form Factors of the Neutron for Timelike Momentum Transfer. PHYSICAL REVIEW LETTERS 2023; 130:151905. [PMID: 37115883 DOI: 10.1103/physrevlett.130.151905] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/15/2022] [Revised: 02/27/2023] [Accepted: 03/23/2023] [Indexed: 06/19/2023]
Abstract
We present the first measurements of the electric and magnetic form factors of the neutron in the timelike (positive q^{2}) region as function of four-momentum transfer. We explored the differential cross sections of the reaction e^{+}e^{-}→n[over ¯]n with data collected with the BESIII detector at the BEPCII accelerator, corresponding to an integrated luminosity of 354.6 pb^{-1} in total at twelve center-of-mass energies between sqrt[s]=2.0-2.95 GeV. A relative uncertainty of 18% and 12% for the electric and magnetic form factors, respectively, is achieved at sqrt[s]=2.3935 GeV. Our results are comparable in accuracy to those from electron scattering in the comparable spacelike region of four-momentum transfer. The electromagnetic form factor ratio R_{em}≡|G_{E}|/|G_{M}| is within the uncertainties close to unity. We compare our result on |G_{E}| and |G_{M}| to recent model predictions, and the measurements in the spacelike region to test the analyticity of electromagnetic form factors.
Collapse
|
83
|
Ablikim M, Achasov MN, Adlarson P, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Batozskaya V, Becker D, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bianco E, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Che GR, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen ZJ, Cheng WS, Choi SK, Chu X, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Duan ZH, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Jang E, Jeong JH, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia ZK, Jiang PC, Jiang SS, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kabana S, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei TT, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JQ, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li SY, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Li YG, Li ZX, Li ZY, Liang C, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu C, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pei YP, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Plura S, Pogodin S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Rashid KH, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Sarantsev A, Schelhaas Y, Schnier C, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen WH, Shen XY, Shi BA, Shi HC, Shi JY, Shi QQ, Shi RS, Shi X, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su PP, Su YJ, Sun GX, Sun H, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian Y, Uman I, Wang B, Wang B, Wang BL, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang S, Wang T, Wang TJ, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang Y, Wang YD, Wang YF, Wang YH, Wang YQ, Wang Y, Wang Z, Wang ZY, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YJ, Wu Z, Xia L, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu XP, Xu YC, Xu ZP, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HL, Yang HX, Yang T, Yang YF, Yang YX, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu T, Yu XD, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zhai XY, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HQ, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZL, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou JH, Zu J. Observation of a New X(3872) Production Process e^{+}e^{-}→ωX(3872). PHYSICAL REVIEW LETTERS 2023; 130:151904. [PMID: 37115900 DOI: 10.1103/physrevlett.130.151904] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/14/2022] [Revised: 03/16/2023] [Accepted: 03/20/2023] [Indexed: 06/19/2023]
Abstract
Using 4.7 fb^{-1} of e^{+}e^{-} collision data at center-of-mass energies from 4.661 to 4.951 GeV collected by the BESIII detector at the BEPCII collider, we observe the X(3872) production process e^{+}e^{-}→ωX(3872) for the first time. The significance is 7.8σ, including both the statistical and systematic uncertainties. The e^{+}e^{-}→ωX(3872) Born cross section and the corresponding upper limit at 90% confidence level at each energy point are reported. The line shape of the cross section indicates that the ωX(3872) signals may be from the decays of some nontrivial structures.
Collapse
|
84
|
Hu SY, Yuan ZC, Lyu CT, Rong CY, Hu Y, Shen Y. [Application progress of endoscopic surgery of artificial stapes in otosclerosis]. ZHONGHUA ER BI YAN HOU TOU JING WAI KE ZA ZHI = CHINESE JOURNAL OF OTORHINOLARYNGOLOGY HEAD AND NECK SURGERY 2023; 58:389-393. [PMID: 37026162 DOI: 10.3760/cma.j.cn115330-20220722-00457] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Grants] [Subscribe] [Scholar Register] [Indexed: 04/08/2023]
|
85
|
Lu S, Han L, Lv D, Zhang Z, Wu J, Wang Q, Dong X, Hu Y, Chen J, Wu L. 80TiP High-dose aumolertinib versus osimertinib in EGFR T790M+ NSCLC patients with brain metastases (ATTACK). J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00334-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
86
|
Chen H, Hu Y, Fan Y, Wu G, Cang S, Yang Y, Yang N, Ma R, Jing G, Liu A, Xu X, Tang S, Cheng Y, Yu Y, Wu YL. 22P Adding anlotinib in gradual or local progression on first-line EGFR-TKIs for advanced non-small cell lung cancer: A single-arm, multicenter, phase II trial. J Thorac Oncol 2023. [DOI: 10.1016/s1556-0864(23)00276-9] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/03/2023]
|
87
|
Dai X, Cao X, Jiang Q, Wu B, Lou T, Shao Y, Hu Y, Lan Q. Neurological complications of COVID-19. QJM 2023; 116:161-180. [PMID: 36484692 DOI: 10.1093/qjmed/hcac272] [Citation(s) in RCA: 6] [Impact Index Per Article: 6.0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 10/07/2022] [Accepted: 12/02/2022] [Indexed: 12/13/2022] Open
Abstract
Corona Virus Disease 2019 (COVID-19) has caused several pandemic peaks worldwide due to its high variability and infectiousness, and COVID-19 has become a long-standing global public health problem. There is growing evidence that severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) frequently causes multi-organ injuries and more severe neurological manifestations. Therefore, increased awareness of possible neurological complications is beneficial in preventing and mitigating the impact of long-term sequelae and improving the prognostic outcome of critically ill patients with COVID-19. Here, we review the main pathways of SARS-CoV-2 neuroinvasion and the potential mechanisms causing neurological damage. We also discuss in detail neurological complications, aiming to provide cutting-edge basis for subsequent related basic research and clinical studies of diagnosis and treatment.
Collapse
|
88
|
Ablikim M, Achasov MN, Adlarson P, Aliberti R, Amoroso A, An MR, An Q, Bai Y, Bakina O, Balossino I, Ban Y, Batozskaya V, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bianco E, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang TT, Chang WL, Che GR, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen YQ, Chen ZJ, Cheng WS, Choi SK, Chu X, Cibinetto G, Coen SC, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding B, Ding XX, Ding Y, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Duan ZH, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Fu YW, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Gramigna S, Greco M, Gu MH, Gu YT, Guan CY, Guan ZL, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, H XT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Holtmann T, Hong PC, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang XT, Huang YP, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Jeong JH, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia ZK, Jiang PC, Jiang SS, Jiang TJ, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, K X, Kabana S, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Khoukaz A, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei TT, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li HB, Li HJ, Li HN, Li H, Li JR, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Li YG, Li ZJ, Li ZX, Li ZY, Liang C, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin DX, Lin T, Liu BX, Liu BJ, Liu C, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu LC, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma JL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pei YP, Pelizaeus M, Peng HP, Peters K, Ping JL, Ping RG, Plura S, Pogodin S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Salone N, Sarantsev A, Schelhaas Y, Schoenning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen WH, Shen XY, Shi BA, Shi HC, Shi JY, Shi QQ, Shi RS, Shi X, Song JJ, Song TZ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su YJ, Sun GB, Sun GX, Sun H, Sun HK, Sun JF, Sun K, Sun L, Sun SS, Sun T, Sun WY, Sun Y, Sun YJ, Sun YZ, Sun ZT, Tan YX, Tang CJ, Tang GY, Tang J, Tang YA, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian WH, Tian Y, Tian ZF, Uman I, Wang B, Wang BL, Wang B, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang M, Wang S, Wang T, Wang TJ, Wang W, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XJ, Wang XL, Wang Y, Wang YD, Wang YF, Wang YH, Wang YN, Wang YQ, Wang Y, Wang Y, Wang Z, Wang ZL, Wang ZY, Wang Z, Wei D, Wei DH, Weidner F, Wen SP, Wenzel CW, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu C, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu YJ, Wu Z, Xia L, Xian XM, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu WL, Xu XP, Xu YC, Xu ZP, Xu ZS, Yan F, Yan L, Yan WB, Yan WC, Yan XQ, Yang HJ, Yang HL, Yang HX, Yang T, Yang Y, Yang YF, Yang YX, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu T, Yu XD, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zeng YJ, Zhai XY, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HQ, Zhang HY, Zhang JJ, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZL, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng WJ, Zheng YH, Zhong B, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu L, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou JH, Zu J. Observation of Three Charmoniumlike States with J^{PC}=1^{--} in e^{+}e^{-}→D^{*0}D^{*-}π^{+}. PHYSICAL REVIEW LETTERS 2023; 130:121901. [PMID: 37027853 DOI: 10.1103/physrevlett.130.121901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 01/18/2023] [Revised: 02/16/2023] [Accepted: 02/24/2023] [Indexed: 06/19/2023]
Abstract
The Born cross sections of the process e^{+}e^{-}→D^{*0}D^{*-}π^{+} at center-of-mass energies from 4.189 to 4.951 GeV are measured for the first time. The data samples used correspond to an integrated luminosity of 17.9 fb^{-1} and were collected by the BESIII detector operating at the BEPCII storage ring. Three enhancements around 4.20, 4.47, and 4.67 GeV are visible. The resonances have masses of 4209.6±4.7±5.9 MeV/c^{2}, 4469.1±26.2±3.6 MeV/c^{2}, and 4675.3±29.5±3.5 MeV/c^{2} and widths of 81.6±17.8±9.0 MeV, 246.3±36.7±9.4 MeV, and 218.3±72.9±9.3 MeV, respectively, where the first uncertainties are statistical and the second systematic. The first and third resonances are consistent with the ψ(4230) and ψ(4660) states, respectively, while the second one is compatible with the ψ(4500) observed in the e^{+}e^{-}→K^{+}K^{-}J/ψ process. These three charmoniumlike ψ states are observed in the e^{+}e^{-}→D^{*0}D^{*-}π^{+} process for the first time.
Collapse
|
89
|
Aboona BE, Adam J, Adamczyk L, Adams JR, Aggarwal I, Aggarwal MM, Ahammed Z, Anderson DM, Aschenauer EC, Atchison J, Bairathi V, Baker W, Ball Cap JG, Barish K, Bellwied R, Bhagat P, Bhasin A, Bhatta S, Bielcik J, Bielcikova J, Brandenburg JD, Cai XZ, Caines H, Calderón de la Barca Sánchez M, Cebra D, Ceska J, Chakaberia I, Chaloupka P, Chan BK, Chang Z, Chen D, Chen J, Chen JH, Chen Z, Cheng J, Cheng Y, Choudhury S, Christie W, Chu X, Crawford HJ, Csanád M, Dale-Gau G, Das A, Daugherity M, Deppner IM, Dhamija A, Di Carlo L, Didenko L, Dixit P, Dong X, Drachenberg JL, Duckworth E, Dunlop JC, Engelage J, Eppley G, Esumi S, Evdokimov O, Ewigleben A, Eyser O, Fatemi R, Fazio S, Feng CJ, Feng Y, Finch E, Fisyak Y, Flor FA, Fu C, Gagliardi CA, Galatyuk T, Geurts F, Ghimire N, Gibson A, Gopal K, Gou X, Grosnick D, Gupta A, Guryn W, Hamed A, Han Y, Harabasz S, Harasty MD, Harris JW, Harrison H, He W, He XH, He Y, Heppelmann S, Herrmann N, Holub L, Hu C, Hu Q, Hu Y, Huang H, Huang HZ, Huang SL, Huang T, Huang X, Huang Y, Huang Y, Humanic TJ, Isenhower D, Isshiki M, Jacobs WW, Jalotra A, Jena C, Jentsch A, Ji Y, Jia J, Jin C, Ju X, Judd EG, Kabana S, Kabir ML, Kagamaster S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kelsey M, Khyzhniak YV, Kikoła DP, Kimelman B, Kincses D, Kisel I, Kiselev A, Knospe AG, Ko HS, Kosarzewski LK, Kramarik L, Kumar L, Kumar S, Kunnawalkam Elayavalli R, Lacey R, Landgraf JM, Lauret J, Lebedev A, Lee JH, Leung YH, Lewis N, Li C, Li C, Li W, Li X, Li Y, Li Y, Li Z, Liang X, Liang Y, Licenik R, Lin T, Lisa MA, Liu C, Liu F, Liu H, Liu H, Liu L, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Lomicky O, Longacre RS, Loyd E, Lu T, Lukow NS, Luo XF, Ma L, Ma R, Ma YG, Magdy N, Mallick D, Margetis S, Markert C, Matis HS, Mazer JA, McNamara G, Mi K, Mioduszewski S, Mohanty B, Mooney I, Mukherjee A, Nagy MI, Nain AS, Nam JD, Nasim M, Neff D, Nelson JM, Nemes DB, Nie M, Niida T, Nishitani R, Nonaka T, Nunes AS, Odyniec G, Ogawa A, Oh S, Okubo K, Page BS, Pak R, Pan J, Pandav A, Pandey AK, Pani T, Paul A, Pawlik B, Pawlowska D, Perkins C, Pluta J, Pokhrel BR, Posik M, Protzman T, Prozorova V, Pruthi NK, Przybycien M, Putschke J, Qin Z, Qiu H, Quintero A, Racz C, Radhakrishnan SK, Raha N, Ray RL, Reed R, Ritter HG, Robertson CW, Robotkova M, Romero JL, Rosales Aguilar MA, Roy D, Roy Chowdhury P, Ruan L, Sahoo AK, Sahoo NR, Sako H, Salur S, Sato S, Schmidke WB, Schmitz N, Seck FJ, Seger J, Seto R, Seyboth P, Shah N, Shanmuganathan PV, Shao M, Shao T, Sharma M, Sharma N, Sharma R, Sharma SR, Sheikh AI, Shen DY, Shen K, Shi SS, Shi Y, Shou QY, Si F, Singh J, Singha S, Sinha P, Skoby MJ, Smirnov N, Söhngen Y, Song Y, Srivastava B, Stanislaus TDS, Stefaniak M, Stewart DJ, Stringfellow B, Su Y, Suaide AAP, Sumbera M, Sun C, Sun X, Sun Y, Sun Y, Surrow B, Sweger ZW, Szymanski P, Tamis A, Tang AH, Tang Z, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Todoroki T, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Truhlar T, Trzeciak BA, Tsai OD, Tsang CY, Tu Z, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vanek J, Vassiliev I, Verkest V, Videbæk F, Voloshin SA, Wang F, Wang G, Wang JS, Wang X, Wang Y, Wang Y, Wang Y, Wang Z, Webb JC, Weidenkaff PC, Westfall GD, Wielanek D, Wieman H, Wilks G, Wissink SW, Witt R, Wu J, Wu J, Wu X, Wu Y, Xi B, Xiao ZG, Xie W, Xu H, Xu N, Xu QH, Xu Y, Xu Y, Xu Z, Xu Z, Yan G, Yan Z, Yang C, Yang Q, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yu Y, Zbroszczyk H, Zha W, Zhang C, Zhang D, Zhang J, Zhang S, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang ZJ, Zhang Z, Zhang Z, Zhao F, Zhao J, Zhao M, Zhou C, Zhou J, Zhou S, Zhou Y, Zhu X, Zurek M, Zyzak M. Measurement of Sequential ϒ Suppression in Au+Au Collisions at sqrt[s_{NN}]=200 GeV with the STAR Experiment. PHYSICAL REVIEW LETTERS 2023; 130:112301. [PMID: 37001106 DOI: 10.1103/physrevlett.130.112301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/14/2022] [Revised: 11/30/2022] [Accepted: 01/26/2023] [Indexed: 06/19/2023]
Abstract
We report on measurements of sequential ϒ suppression in Au+Au collisions at sqrt[s_{NN}]=200 GeV with the STAR detector at the Relativistic Heavy Ion Collider (RHIC) through both the dielectron and dimuon decay channels. In the 0%-60% centrality class, the nuclear modification factors (R_{AA}), which quantify the level of yield suppression in heavy-ion collisions compared to p+p collisions, for ϒ(1S) and ϒ(2S) are 0.40±0.03(stat)±0.03(sys)±0.09(norm) and 0.26±0.08(stat)±0.02(sys)±0.06(norm), respectively, while the upper limit of the ϒ(3S) R_{AA} is 0.17 at a 95% confidence level. This provides experimental evidence that the ϒ(3S) is significantly more suppressed than the ϒ(1S) at RHIC. The level of suppression for ϒ(1S) is comparable to that observed at the much higher collision energy at the Large Hadron Collider. These results point to the creation of a medium at RHIC whose temperature is sufficiently high to strongly suppress excited ϒ states.
Collapse
|
90
|
Hu Y, Lu T, Zhang H, Fang M, Chen B, Guo Q, Lin S, Wang Y, Feng P, Gong X, Pan J, Li J, Xia Y. 38P Locoregional radiotherapy improves survival outcomes in de novo metastatic nasopharyngeal carcinoma treated with chemoimmunotherapy. ESMO Open 2023. [DOI: 10.1016/j.esmoop.2023.101004] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 04/05/2023] Open
|
91
|
Da JJ, Sun Y, Chen JC, Li Q, Yang YQ, He S, Yang NY, He PH, Hu Y, Long YJ, Yuan J, Zha Y. [Effect of hemoperfusion on protein energy wasting and long-term prognosis in patients on maintenance hemodialysis]. ZHONGHUA YI XUE ZA ZHI 2023; 103:559-565. [PMID: 36822866 DOI: 10.3760/cma.j.cn112137-20220925-02022] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/25/2023]
Abstract
Objective: To explore the effect of hemoperfusion (HP) combined with hemodialysis (HD) (HD+HP) on protein energy wasting (PEW) and long-term prognosis in patients on maintenance HD (MHD). Methods: A prospective multicenter cohort study was conducted. Adult MHD patients who completed PEW assessment and underwent regular dialysis between July 2015 and July 2021 at 23 hemodialysis centers in Guizhou Province were selected. Demographic characteristics, physical indicators, laboratory indicators, 3-day diet diary and HP treatment data of the subjects were collected. The patients were divided into different groups according to the presence or absence of HP, the frequency of HP treatment and the type of cartridge, and then relevant indicators were compared. Multivariate logistic regression model and Cox proportional regression model were used to analyze the influence of HP treatment on PEW risk in MHD patients. Meanwhile, Kaplan-Meier method was used to plot the survival curve. Results: A total of 4 623 MHD patients (2 789 males and 1 834 females) aged (53.7±15.9) years were included in the study, with a median dialysis age of 64.3 (44.3, 92.3) months. There were 3 429 (74.2%) MHD patients treated with HD+HP, and 1 194 patients (25.8%) were not treated with HP. According to the 2008 diagnostic criteria of the International Society for Renal Nutrition and Metabolism (ISRNM), the incidence of PEW was 26.0% (1 204/4 623). Multivariate logistic regression analysis showed that female (OR=2.48, 95%CI: 1.55-3.95, P<0.001), diabetes (OR=1.75, 95%CI: 1.08-2.83, P=0.024) and high-sensitivity C-reactive protein (hs-CRP) (OR=1.02, 95%CI: 1.01-1.03, P=0.003) were risk factors for PEW, while treatment with HD+HP (OR=0.51, 95%CI: 0.31-0.87, P=0.012) and elevated triglyceride levels (OR=0.62, 95%CI: 0.48-0.80, P<0.001) were protective factors. Cox hazard ratio regression showed that among different HP treatment frequencies and cartridge types, 2 times/month (HR=0.40, 95%CI: 0.17-0.95, P=0.037), 3 times/month (HR=0.44, 95%CI: 0.23-0.85, P=0.014), 4 times/month (HR=0.54, 95%CI: 0.34-0.85, P=0.008), HA130 (HR=0.57, 95%CI: 0.36-0.89, P=0.014) and HA230 (HR=0.30, 95%CI: 0.15-0.63, P=0.001) had protective effects on the occurrence of PEW in MHD patients. The all-cause mortality rate was 11.3% (521/4 623) at 33 (24, 48) months of follow-up. Kaplan-Meier analysis showed that patients undergoing 4 times/month HP treatment (χ2=36.78, P<0.001) and using HA230 (χ2=9.46, P=0.002) had the highest survival rate. Conclusion: Treatment with HD+HP is a protective factor for PEW in patients with MHD, and 4 times/month HP treatment or HA230 significantly reduces the risk of PEW and all-cause mortality in patients with MHD.
Collapse
|
92
|
Ablikim M, Achasov MN, Adlarson P, Albrecht M, Aliberti R, Amoroso A, An MR, An Q, Bai XH, Bai Y, Bakina O, Baldini Ferroli R, Balossino I, Ban Y, Batozskaya V, Becker D, Begzsuren K, Berger N, Bertani M, Bettoni D, Bianchi F, Bloms J, Bortone A, Boyko I, Briere RA, Brueggemann A, Cai H, Cai X, Calcaterra A, Cao GF, Cao N, Cetin SA, Chang JF, Chang WL, Chelkov G, Chen C, Chen C, Chen G, Chen HS, Chen ML, Chen SJ, Chen SM, Chen T, Chen XR, Chen XT, Chen YB, Chen ZJ, Cheng WS, Chu X, Cibinetto G, Cossio F, Cui JJ, Dai HL, Dai JP, Dbeyssi A, de Boer RE, Dedovich D, Deng ZY, Denig A, Denysenko I, Destefanis M, De Mori F, Ding Y, Dong J, Dong LY, Dong MY, Dong X, Du SX, Egorov P, Fan YL, Fang J, Fang SS, Fang WX, Fang Y, Farinelli R, Fava L, Feldbauer F, Felici G, Feng CQ, Feng JH, Fischer K, Fritsch M, Fritzsch C, Fu CD, Gao H, Gao YN, Gao Y, Garbolino S, Garzia I, Ge PT, Ge ZW, Geng C, Gersabeck EM, Gilman A, Goetzen K, Gong L, Gong WX, Gradl W, Greco M, Gu LM, Gu MH, Gu YT, Guan CY, Guo AQ, Guo LB, Guo RP, Guo YP, Guskov A, Han TT, Han WY, Hao XQ, Harris FA, He KK, He KL, Heinsius FH, Heinz CH, Heng YK, Herold C, Himmelreich M, Hou GY, Hou YR, Hou ZL, Hu HM, Hu JF, Hu T, Hu Y, Huang GS, Huang KX, Huang LQ, Huang LQ, Huang XT, Huang YP, Huang Z, Hussain T, Hüsken N, Imoehl W, Irshad M, Jackson J, Jaeger S, Janchiv S, Ji Q, Ji QP, Ji XB, Ji XL, Ji YY, Jia ZK, Jiang HB, Jiang SS, Jiang XS, Jiang Y, Jiao JB, Jiao Z, Jin S, Jin Y, Jing MQ, Johansson T, Kalantar-Nayestanaki N, Kang XL, Kang XS, Kappert R, Kavatsyuk M, Ke BC, Keshk IK, Khoukaz A, Kiese P, Kiuchi R, Kliemt R, Koch L, Kolcu OB, Kopf B, Kuemmel M, Kuessner M, Kupsc A, Kühn W, Lane JJ, Lange JS, Larin P, Lavania A, Lavezzi L, Lei ZH, Leithoff H, Lellmann M, Lenz T, Li C, Li C, Li CH, Li C, Li DM, Li F, Li G, Li H, Li H, Li HB, Li HJ, Li HN, Li JQ, Li JS, Li JW, Li K, Li LJ, Li LK, Li L, Li MH, Li PR, Li SX, Li SY, Li T, Li WD, Li WG, Li XH, Li XL, Li X, Liang H, Liang H, Liang H, Liang YF, Liang YT, Liao GR, Liao LZ, Libby J, Limphirat A, Lin CX, Lin DX, Lin T, Liu BJ, Liu CX, Liu D, Liu FH, Liu F, Liu F, Liu GM, Liu H, Liu HB, Liu HM, Liu H, Liu H, Liu JB, Liu JL, Liu JY, Liu K, Liu KY, Liu K, Liu L, Liu MH, Liu PL, Liu Q, Liu SB, Liu T, Liu WK, Liu WM, Liu X, Liu Y, Liu YB, Liu ZA, Liu ZQ, Lou XC, Lu FX, Lu HJ, Lu JG, Lu XL, Lu Y, Lu YP, Lu ZH, Luo CL, Luo MX, Luo T, Luo XL, Lyu XR, Lyu YF, Ma FC, Ma HL, Ma LL, Ma MM, Ma QM, Ma RQ, Ma RT, Ma XY, Ma Y, Maas FE, Maggiora M, Maldaner S, Malde S, Malik QA, Mangoni A, Mao YJ, Mao ZP, Marcello S, Meng ZX, Messchendorp JG, Mezzadri G, Miao H, Min TJ, Mitchell RE, Mo XH, Muchnoi NY, Nefedov Y, Nerling F, Nikolaev IB, Ning Z, Nisar S, Niu Y, Olsen SL, Ouyang Q, Pacetti S, Pan X, Pan Y, Pathak A, Pathak A, Pelizaeus M, Peng HP, Peters K, Pettersson J, Ping JL, Ping RG, Plura S, Pogodin S, Prasad V, Qi FZ, Qi H, Qi HR, Qi M, Qi TY, Qian S, Qian WB, Qian Z, Qiao CF, Qin JJ, Qin LQ, Qin XP, Qin XS, Qin ZH, Qiu JF, Qu SQ, Qu SQ, Rashid KH, Redmer CF, Ren KJ, Rivetti A, Rodin V, Rolo M, Rong G, Rosner C, Ruan SN, Sang HS, Sarantsev A, Schelhaas Y, Schnier C, Schönning K, Scodeggio M, Shan KY, Shan W, Shan XY, Shangguan JF, Shao LG, Shao M, Shen CP, Shen HF, Shen XY, Shi BA, Shi HC, Shi JY, Shi QQ, Shi RS, Shi X, Shi XD, Song JJ, Song WM, Song YX, Sosio S, Spataro S, Stieler F, Su KX, Su PP, Su YJ, Sun GX, Sun H, Sun HK, Sun JF, Sun L, Sun SS, Sun T, Sun WY, Sun X, Sun YJ, Sun YZ, Sun ZT, Tan YH, Tan YX, Tang CJ, Tang GY, Tang J, Tao LY, Tao QT, Tat M, Teng JX, Thoren V, Tian WH, Tian Y, Uman I, Wang B, Wang BL, Wang CW, Wang DY, Wang F, Wang HJ, Wang HP, Wang K, Wang LL, Wang M, Wang MZ, Wang M, Wang S, Wang T, Wang TJ, Wang W, Wang WH, Wang WP, Wang X, Wang XF, Wang XL, Wang YD, Wang YF, Wang YH, Wang YQ, Wang YQ, Wang Y, Wang Z, Wang ZY, Wang Z, Wei DH, Weidner F, Wen SP, White DJ, Wiedner U, Wilkinson G, Wolke M, Wollenberg L, Wu JF, Wu LH, Wu LJ, Wu X, Wu XH, Wu Y, Wu Z, Xia L, Xiang T, Xiao D, Xiao GY, Xiao H, Xiao SY, Xiao YL, Xiao ZJ, Xie C, Xie XH, Xie Y, Xie YG, Xie YH, Xie ZP, Xing TY, Xu CF, Xu CJ, Xu GF, Xu HY, Xu QJ, Xu SY, Xu XP, Xu YC, Xu ZP, Yan F, Yan L, Yan WB, Yan WC, Yang HJ, Yang HL, Yang HX, Yang L, Yang SL, Yang T, Yang YX, Yang Y, Ye M, Ye MH, Yin JH, You ZY, Yu BX, Yu CX, Yu G, Yu T, Yuan CZ, Yuan L, Yuan SC, Yuan XQ, Yuan Y, Yuan ZY, Yue CX, Zafar AA, Zeng FR, Zeng X, Zeng Y, Zhan YH, Zhang AQ, Zhang BL, Zhang BX, Zhang DH, Zhang GY, Zhang H, Zhang HH, Zhang HH, Zhang HY, Zhang JL, Zhang JQ, Zhang JW, Zhang JX, Zhang JY, Zhang JZ, Zhang J, Zhang J, Zhang LM, Zhang LQ, Zhang L, Zhang P, Zhang QY, Zhang S, Zhang XD, Zhang XM, Zhang XY, Zhang XY, Zhang Y, Zhang YT, Zhang YH, Zhang Y, Zhang Y, Zhang ZH, Zhang ZY, Zhang ZY, Zhao G, Zhao J, Zhao JY, Zhao JZ, Zhao L, Zhao L, Zhao MG, Zhao Q, Zhao SJ, Zhao YB, Zhao YX, Zhao ZG, Zhemchugov A, Zheng B, Zheng JP, Zheng YH, Zhong B, Zhong C, Zhong X, Zhou H, Zhou LP, Zhou X, Zhou XK, Zhou XR, Zhou XY, Zhou YZ, Zhu J, Zhu K, Zhu KJ, Zhu LX, Zhu SH, Zhu SQ, Zhu TJ, Zhu WJ, Zhu YC, Zhu ZA, Zou BS, Zou JH. Evidence for the Cusp Effect in η' Decays into ηπ^{0}π^{0}. PHYSICAL REVIEW LETTERS 2023; 130:081901. [PMID: 36898113 DOI: 10.1103/physrevlett.130.081901] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/06/2022] [Revised: 11/19/2022] [Accepted: 01/20/2023] [Indexed: 06/18/2023]
Abstract
Using a sample of 4.3×10^{5} η^{'}→ηπ^{0}π^{0} events selected from the ten billion J/ψ event dataset collected with the BESIII detector, we study the decay η^{'}→ηπ^{0}π^{0} within the framework of nonrelativistic effective field theory. Evidence for a structure at π^{+}π^{-} mass threshold is observed in the invariant mass spectrum of π^{0}π^{0} with a statistical significance of around 3.5σ, which is consistent with the cusp effect as predicted by the nonrelativistic effective field theory. After introducing the amplitude for describing the cusp effect, the ππ scattering length combination a_{0}-a_{2} is determined to be 0.226±0.060_{stat}±0.013_{syst}, which is in good agreement with theoretical calculation of 0.2644±0.0051.
Collapse
|
93
|
Aboona BE, Adam J, Adamczyk L, Adams JR, Aggarwal I, Aggarwal MM, Ahammed Z, Anderson DM, Aschenauer EC, Atchison J, Bairathi V, Baker W, Ball Cap JG, Barish K, Bellwied R, Bhagat P, Bhasin A, Bhatta S, Bielcik J, Bielcikova J, Brandenburg JD, Cai XZ, Caines H, Calderón de la Barca Sánchez M, Cebra D, Ceska J, Chakaberia I, Chaloupka P, Chan BK, Chang Z, Chen D, Chen J, Chen JH, Chen Z, Cheng J, Cheng Y, Choudhury S, Christie W, Chu X, Crawford HJ, Csanád M, Dale-Gau G, Das A, Daugherity M, Deppner IM, Dhamija A, Di Carlo L, Didenko L, Dixit P, Dong X, Drachenberg JL, Duckworth E, Dunlop JC, Engelage J, Eppley G, Esumi S, Evdokimov O, Ewigleben A, Eyser O, Fatemi R, Fazio S, Feng CJ, Feng Y, Finch E, Fisyak Y, Flor FA, Fu C, Gagliardi CA, Galatyuk T, Geurts F, Ghimire N, Gibson A, Gopal K, Gou X, Grosnick D, Gupta A, Guryn W, Hamed A, Han Y, Harabasz S, Harasty MD, Harris JW, Harrison H, He W, He XH, He Y, Heppelmann S, Herrmann N, Holub L, Hu C, Hu Q, Hu Y, Huang H, Huang HZ, Huang SL, Huang T, Huang X, Huang Y, Huang Y, Humanic TJ, Isenhower D, Isshiki M, Jacobs WW, Jalotra A, Jena C, Jentsch A, Ji Y, Jia J, Jin C, Ju X, Judd EG, Kabana S, Kabir ML, Kagamaster S, Kalinkin D, Kang K, Kapukchyan D, Kauder K, Ke HW, Keane D, Kelsey M, Khyzhniak YV, Kikoła DP, Kimelman B, Kincses D, Kisel I, Kiselev A, Knospe AG, Ko HS, Kosarzewski LK, Kramarik L, Kumar L, Kumar S, Kunnawalkam Elayavalli R, Lacey R, Landgraf JM, Lauret J, Lebedev A, Lee JH, Leung YH, Lewis N, Li C, Li C, Li W, Li X, Li Y, Li Y, Li Z, Liang X, Liang Y, Licenik R, Lin T, Lisa MA, Liu C, Liu F, Liu H, Liu H, Liu L, Liu T, Liu X, Liu Y, Liu Z, Ljubicic T, Llope WJ, Lomicky O, Longacre RS, Loyd E, Lu T, Lukow NS, Luo XF, Ma L, Ma R, Ma YG, Magdy N, Mallick D, Margetis S, Markert C, Matis HS, Mazer JA, McNamara G, Mi K, Mioduszewski S, Mohanty B, Mooney I, Mukherjee A, Nagy MI, Nain AS, Nam JD, Nasim M, Neff D, Nelson JM, Nemes DB, Nie M, Niida T, Nishitani R, Nonaka T, Nunes AS, Odyniec G, Ogawa A, Oh S, Okubo K, Page BS, Pak R, Pan J, Pandav A, Pandey AK, Pani T, Paul A, Pawlik B, Pawlowska D, Perkins C, Pluta J, Pokhrel BR, Posik M, Protzman T, Prozorova V, Pruthi NK, Przybycien M, Putschke J, Qin Z, Qiu H, Quintero A, Racz C, Radhakrishnan SK, Raha N, Ray RL, Reed R, Ritter HG, Robertson CW, Robotkova M, Romero JL, Rosales Aguilar MA, Roy D, Roy Chowdhury P, Ruan L, Sahoo AK, Sahoo NR, Sako H, Salur S, Sato S, Schmidke WB, Schmitz N, Seck FJ, Seger J, Seto R, Seyboth P, Shah N, Shanmuganathan PV, Shao M, Shao T, Sharma M, Sharma N, Sharma R, Sharma SR, Sheikh AI, Shen DY, Shen K, Shi SS, Shi Y, Shou QY, Si F, Singh J, Singha S, Sinha P, Skoby MJ, Smirnov N, Söhngen Y, Song Y, Srivastava B, Stanislaus TDS, Stefaniak M, Stewart DJ, Stringfellow B, Su Y, Suaide AAP, Sumbera M, Sun C, Sun X, Sun Y, Sun Y, Surrow B, Sweger ZW, Szymanski P, Tamis A, Tang AH, Tang Z, Tarnowsky T, Thomas JH, Timmins AR, Tlusty D, Todoroki T, Tomkiel CA, Trentalange S, Tribble RE, Tribedy P, Truhlar T, Trzeciak BA, Tsai OD, Tsang CY, Tu Z, Ullrich T, Underwood DG, Upsal I, Van Buren G, Vanek J, Vassiliev I, Verkest V, Videbæk F, Voloshin SA, Wang F, Wang G, Wang JS, Wang X, Wang Y, Wang Y, Wang Y, Wang Z, Webb JC, Weidenkaff PC, Westfall GD, Wielanek D, Wieman H, Wilks G, Wissink SW, Witt R, Wu J, Wu J, Wu X, Wu Y, Xi B, Xiao ZG, Xie W, Xu H, Xu N, Xu QH, Xu Y, Xu Y, Xu Z, Xu Z, Yan G, Yan Z, Yang C, Yang Q, Yang S, Yang Y, Ye Z, Ye Z, Yi L, Yip K, Yu Y, Zbroszczyk H, Zha W, Zhang C, Zhang D, Zhang J, Zhang S, Zhang X, Zhang Y, Zhang Y, Zhang Y, Zhang ZJ, Zhang Z, Zhang Z, Zhao F, Zhao J, Zhao M, Zhou C, Zhou J, Zhou S, Zhou Y, Zhu X, Zurek M, Zyzak M. Beam Energy Dependence of Fifth- and Sixth-Order Net-Proton Number Fluctuations in Au+Au Collisions at RHIC. PHYSICAL REVIEW LETTERS 2023; 130:082301. [PMID: 36898098 DOI: 10.1103/physrevlett.130.082301] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Received: 07/22/2022] [Revised: 11/21/2022] [Accepted: 01/11/2023] [Indexed: 06/18/2023]
Abstract
We report the beam energy and collision centrality dependence of fifth and sixth order cumulants (C_{5}, C_{6}) and factorial cumulants (κ_{5}, κ_{6}) of net-proton and proton number distributions, from center-of-mass energy (sqrt[s_{NN}]) 3 GeV to 200 GeV Au+Au collisions at RHIC. Cumulant ratios of net-proton (taken as proxy for net-baryon) distributions generally follow the hierarchy expected from QCD thermodynamics, except for the case of collisions at 3 GeV. The measured values of C_{6}/C_{2} for 0%-40% centrality collisions show progressively negative trend with decreasing energy, while it is positive for the lowest energy studied. These observed negative signs are consistent with QCD calculations (for baryon chemical potential, μ_{B}≤110 MeV) which contains the crossover transition range. In addition, for energies above 7.7 GeV, the measured proton κ_{n}, within uncertainties, does not support the two-component (Poisson+binomial) shape of proton number distributions that would be expected from a first-order phase transition. Taken in combination, the hyperorder proton number fluctuations suggest that the structure of QCD matter at high baryon density, μ_{B}∼750 MeV at sqrt[s_{NN}]=3 GeV is starkly different from those at vanishing μ_{B}∼24 MeV at sqrt[s_{NN}]=200 GeV and higher collision energies.
Collapse
|
94
|
Jiang T, Hu Y, Cao J. [The role of sinusoidal endothelial cells in liver injury: a review]. ZHONGGUO XUE XI CHONG BING FANG ZHI ZA ZHI = CHINESE JOURNAL OF SCHISTOSOMIASIS CONTROL 2023; 35:92-97. [PMID: 36974022 DOI: 10.16250/j.32.1374.2022118] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Subscribe] [Scholar Register] [Indexed: 03/29/2023]
Abstract
Liver sinusoidal endothelial cells (LSECs) locate on the surface of hepatic sinusoids. As the first line of defense between the liver and blood, LSECs are the most abundant non-parenchymal cells in the liver. Under physiological conditions, LSECs may induce liver immune tolerance through participating in substance transport and metabolic waste removal, thereby maintaining liver homeostasis, and under pathological conditions, LSECs may promote liver immune response via antigen presentation. LSECs have been found to play a crucial regulatory role in maintaining the balance between liver regeneration and liver fibrosis. This article reviews the progress of researches on LSECs functions, LSECs changes in liver injury, signal pathways associated with regulation of LSECs functions, and the interaction between LSECs and other types of cells in the liver, aiming to elucidate the function of LSECs and their roles in liver diseases.
Collapse
|
95
|
Sui HJ, Zhen Z, Wang QG, Cong TC, Huang JJ, Hu Y. [A real world study of anti-IgE monoclonal antibody in the treatment of allergic united airway disease]. ZHONGHUA YU FANG YI XUE ZA ZHI [CHINESE JOURNAL OF PREVENTIVE MEDICINE] 2023; 57:273-280. [PMID: 36797588 DOI: 10.3760/cma.j.cn112150-20220808-00798] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/18/2023]
Abstract
Objective: To investigate the clinical efficacy and safety of anti-IgE monoclonal antibody (omazumab) in the treatment of allergic united airway disease (UAD) in the real-wold. Methods: Retrospective cohort study summarizes the case data of patients with allergic united airway disease who were treated with anti IgE monoclonal antibody (omalizumab) for more than 16 weeks from March 1, 2018 to June 30, 2022 in the Peking University First Hospital.The allergic UAD is defined as allergic asthma combined with allergic rhinitis (AA+AR) or allergic asthma combined with chronic sinusitis with nasal polyps (AA+CRSwNP) or allergic asthma combined with allergic rhinitis and nasal polyps (AA+AR+CRSwNP). The control of asthma was evaluated by asthma control test (ACT), lung function test and fractional exhaled nitric oxide (FeNO). The AR was assessed by total nasal symptom score (TNSS). The CRSwNP was evaluated by nasal visual analogue scale (n-VAS), sino-nasal outcome test-22 (SNOT-22), nasal polyps score (TPS) and Lund-Mackay sinus CT grading system. The global evaluation of omalizumab for the treatment of allergic UADwas performed by Global Evaluation of Treatment Effectiveness(GETE).The drug-related side effects were also recorded. Matched t test and Wilcoxon signed-rank test were used to compare the score changes of IgE monoclonal antibody (omazumab) before and after treatment, and multivariate logistic regression analysis was used to determine the influencing factors of IgE monoclonal antibody (omazumab) response. Results: A total of 117 patients with UAD were enrolled, ranging in age from 19 to 77 years; The median age of patients was 48.7 years; Among them, 60 were male, ranging from 19 to 77 years old, with a median age of 49.9 years; There were 57 females, ranging from 19 to 68 years old, with a median age of 47.2 years. There were 32 cases in AA+AR subgroup, 59 cases in AA+CRSwNP subgroup, and 26 cases in AA+AR+CRSwNP subgroup. The total serum IgE level was 190.5 (103.8,391.3) IU/ml. The treatment course of anti IgE monoclonal antibody was 24 (16, 32) weeks. Compared with pre-treatment, omalizumab increased ACT from 20.0 (19.5,22.0) to 24.0 (23.0,25.0) (Z=-8.537, P<0.001), increased pre-bronchodilator FEV1 from 90.2 (74.8,103.0)% predicted value to 95.4 (83.2,106.0)% predicted value (Z=-5.315,P<0.001), increased FEV1/FVC from 80.20 (66.83,88.38)% to 82.72 (71.26,92.25)% (Z=-4.483,P<0.001), decreased FeNO from(49.1±24.8) ppb to (32.8±24.4) ppb (t=5.235, P<0.001), decreased TNSS from (6.5±2.6)to (2.4±1.9) (t=14.171, P<0.001), decreased n-VAS from (6.8±1.2) to (3.4±2.0)(t=14.448, P<0.001), decreased SNOT-22 from (40.0±7.9) to (21.3±10.2)(t=15.360, P<0.001), decreased TPS from (4.1±0.8) to (2.4±1.0)(t=14.718, P<0.001) and decreased Lund-Mackay CT score from (6.0±1.3) to (3.1±1.6)(t=17.012, P<0.001). The global response rate to omalizumab was 67.5%(79/117). The response rate in AA+AR (90.6%,29/32) was significantly higher than that in AA+CRSwNP (61.0%,36/59) and AA+AR+CRSwNP (53.8%,14/26) subgroups (χ2=11.144,P=0.004). Only 4 patients (3.4%,4/117) had mild side effects. Conclusion: The real-world study showed favorable effectiveness and safety of anti-IgE monoclonal antibody for treatment of allergic UAD. To provide basis for preventing the progress and precise treatment of allergic UAD.
Collapse
|
96
|
Hu Y, Li K, Swahn H, Ordoukhanian P, Head SR, Natarajan P, Woods AK, Joseph SB, Johnson KA, Lotz MK. Transcriptomic analyses of joint tissues during osteoarthritis development in a rat model reveal dysregulated mechanotransduction and extracellular matrix pathways. Osteoarthritis Cartilage 2023; 31:199-212. [PMID: 36354073 PMCID: PMC9892293 DOI: 10.1016/j.joca.2022.10.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 04/20/2022] [Revised: 09/20/2022] [Accepted: 10/03/2022] [Indexed: 11/08/2022]
Abstract
OBJECTIVE Transcriptomic changes in joint tissues during the development of osteoarthritis (OA) are of interest for the discovery of biomarkers and mechanisms of disease. The objective of this study was to use the rat medial meniscus transection (MMT) model to discover stage and tissue-specific transcriptomic changes. DESIGN Sham or MMT surgeries were performed in mature rats. Cartilage, menisci and synovium were scored for histopathological changes at 2, 4 and 6 weeks post-surgery and processed for RNA-sequencing. Differentially expressed genes (DEG) were used to identify pathways and mechanisms. Published transcriptomic datasets from animal models and human OA were used to confirm and extend present findings. RESULTS The total number of DEGs was already high at 2 weeks (723 in meniscus), followed by cartilage (259) and synovium (42) and declined to varying degrees in meniscus and synovium but increased in cartilage at 6 weeks. The most upregulated genes included tenascins. The 'response to mechanical stimulus' and extracellular matrix-related pathways were enriched in both cartilage and meniscus. Pathways that were enriched in synovium at 4 weeks indicate processes related to synovial hyperplasia and fibrosis. Synovium also showed upregulation of IL-11 and several MMPs. The mechanical stimulus pathway included upregulation of the mechanoreceptors PIEZO1, PIEZO2 and TRPV4 and nerve growth factor. Analysis of data from prior RNA-sequencing studies of animal models and human OA support these findings. CONCLUSION These results indicate several shared pathways that are affected during OA in cartilage and meniscus and support the role of mechanotransduction and other pathways in OA pathogenesis.
Collapse
|
97
|
Huang H, Siewerdsen JH, Lu A, Hu Y, Zbijewski W, Unberath M, Weiss CR, Sisniega A. Multi-Stage Adaptive Spline Autofocus (MASA) with a Learned Metric for Deformable Motion Compensation in Interventional Cone-Beam CT. PROCEEDINGS OF SPIE--THE INTERNATIONAL SOCIETY FOR OPTICAL ENGINEERING 2023; 12463:1246314. [PMID: 37937146 PMCID: PMC10629227 DOI: 10.1117/12.2654361] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/09/2023]
Abstract
Purpose Cone-beam CT (CBCT) is widespread in abdominal interventional imaging, but its long acquisition time makes it susceptible to patient motion. Image-based autofocus has shown success in CBCT deformable motion compensation, via deep autofocus metrics and multi-region optimization, but it is challenged by the large parameter dimensionality required to capture intricate motion trajectories. This work leverages the differentiable nature of deep autofocus metrics to build a novel optimization strategy, Multi-Stage Adaptive Spine Autofocus (MASA), for compensation of complex deformable motion in abdominal CBCT. Methods MASA poses the autofocus problem as a multi-stage adaptive sampling strategy of the motion trajectory, sampled with Hermite spline basis with variable amplitude and knot temporal positioning. The adaptive method permits simultaneous optimization of the sampling phase, local temporal sampling density, and time-dependent amplitude of the motion trajectory. The optimization is performed in a multi-stage schedule with increasing number of knots that progressively accommodates complex trajectories in late stages, preconditioned by coarser components from early stages, and with minimal increase in dimensionality. MASA was evaluated in controlled simulation experiments with two types of motion trajectories: i) combinations of slow drifts with sudden jerk (sigmoid) motion; and ii) combinations of periodic motion sources of varying frequency into multi-frequency trajectories. Further validation was obtained in clinical data from liver CBCT featuring motion of contrast-enhanced vessels, and soft-tissue structures. Results The adaptive sampling strategy provided successful motion compensation in sigmoid trajectories, compared to fixed sampling strategies (mean SSIM increase of 0.026 compared to 0.011). Inspection of the estimated motion showed the capability of MASA to automatically allocate larger sampling density to parts of the scan timeline featuring sudden motion, effectively accommodating complex motion without increasing the problem dimension. Experiments on multi-frequency trajectories with 3-stage MASA (5, 10, and 15 knots) yielded a twofold SSIM increase compared to single-stage autofocus with 15 knots (0.076 vs 0.040, respectively). Application of MASA to clinical datasets resulted in simultaneous improvement on the delineation of both contrast-enhanced vessels and soft-tissue structures in the liver. Conclusion A new autofocus framework, MASA, was developed including a novel multi-stage technique for adaptive temporal sampling of the motion trajectory in combination with fully differentiable deep autofocus metrics. This novel adaptive sampling approach is a crucial step for application of deformable motion compensation to complex temporal motion trajectories.
Collapse
|
98
|
Cao Y, Hu Y, Jin XF, Liu Y, Zou JM. Dimethyl fumarate attenuates MSU-induced gouty arthritis by inhibiting NLRP3 inflammasome activation and oxidative stress. EUROPEAN REVIEW FOR MEDICAL AND PHARMACOLOGICAL SCIENCES 2023; 27:628-641. [PMID: 36734707 DOI: 10.26355/eurrev_202301_31064] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Subscribe] [Scholar Register] [Indexed: 02/04/2023]
Abstract
OBJECTIVE Dimethyl fumarate (DMF) has shown anti-inflammatory and antioxidant activities. However, the effects of DMF on gouty arthritis remain elusive, and the underlying mechanism is not understood. In this study, we aim to investigate the role of DMF in gouty arthritis. MATERIALS AND METHODS Mice were gavage with DMF for consecutive 7 days at two different doses (10 mg/kg/day or 30 mg/kg/day, once daily) in advance and then monosodium sodium urate (MSU) was injected into their joint to establish an acute gout mice model. The pain and swelling of the hind paw in mice were determined. The production of pro-inflammatory cytokine in the paw tissues was assessed by Elisa and the inflammatory infiltration of the joint was determined by hematoxylin and eosin (H&E) staining. The activity of superoxide dismutase (SOD) and the content of malondialdehyde (MDA) in the tissues were measured by commercial kits. In addition, the expression of nuclear factor kappa B (NF-κB) and NACHT, LRR, and PYD domains-containing protein 3 (NLRP3) inflammasome and downstream genes were detected by PCR and Western blot. Furthermore, LPS-primed murine macrophages Raw 264.7 cells were treated with different concentrations of DMF (2 μM, 5 μM, 10 μM) for 2 h, and then challenged with MSU (200 μg/mL) for other 12 h to observe the effect of DMF on cell viability via cell counting kit-8 (CCK-8) assay and lactate dehydrogenase (LDH) levels in the supernatant of culture medium. Immunofluorescent staining was used to detect the NLRP3 inflammasome activation and reactive oxygen species (ROS) production in vitro. Caspase-1 activity was measured by corresponding assay kits both in vivo and in vitro. RESULTS DMF attenuated pain and swelling in MSU-induced gout mice by decreasing pro-inflammatory cytokine production and inflammatory cell infiltration, as well as improved oxidative stress. Moreover, DMF inhibited the activation of NF-κB and NLRP3 inflammasome and subsequent expression of caspase-1, interleukin-1β (IL-1β), and IL-18 at both mRNA and protein levels. Meanwhile, DMF suppressed NLRP3 inflammasome expression and ROS production in LPS and MSU-stimulated Raw 264.7 cells, thereby protecting the cells from inflammatory injury. CONCLUSIONS DMF serves as a new approach for the treatment of MSU-induced gouty arthritis by suppressing NLRP3 inflammasome activation and oxidative stress.
Collapse
|
99
|
Wang X, Jiang J, Hu W, Hu Y, Qin LQ, Hao Y, Dong JY. Dynapenic Abdominal Obesity and Risk of Heart Disease among Middle-Aged and Older Adults: A Prospective Cohort Study. J Nutr Health Aging 2023; 27:752-758. [PMID: 37754215 DOI: 10.1007/s12603-023-1975-0] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/05/2023] [Accepted: 07/29/2023] [Indexed: 09/28/2023]
Abstract
OBJECTIVES The vicious cycle of dynapenia and abdominal obesity may have synergistic detrimental impacts on health. We aim to investigate the prospective association between dynapenic abdominal obesity and the risk of heart disease among middle-aged and older adults. DESIGN A prospective cohort study. SETTING English Longitudinal Study of Ageing, 2002-2019. PARTICIPANTS A total of 4734 participants aged 50 years and older were included. MEASUREMENTS Individuals were divided into non-dynapenia/non-abdominal obesity (ND/NAO), non-dynapenia/abdominal obesity (ND/AO), dynapenia/non-abdominal obesity (D/NAO), and dynapenia/abdominal obesity (D/AO) according to grip strength and waist circumference at baseline. The Cox proportional hazards models were used to obtain the hazard ratios (HRs) of incident heart disease associated with dynapenia and abdominal obesity after adjusting for potential confounding factors. RESULTS During a median follow-up of 9.5 years, 1040 cases of heart disease were recorded. Compared with ND/NAO group, the multivariable HRs were 1.05 (0.92, 1.21) for ND/AO group, 1.31 (0.96, 1.81) for D/NAO group, and 1.39 (1.03, 1.88) for D/AO group. The significant association of D/AO with incident heart disease was detected in women but not in men [HR = 1.55 (1.07, 2.24) and 1.06 (0.60, 1.88), respectively]. Among middle-aged adults, significant associations of D/NAO and D/AO with incident heart disease were observed [HR = 2.46 (1.42, 4.29) and 1.74 (1.02, 2.97), respectively]. CONCLUSION Both D/NAO and D/AO might increase the risk of developing heart disease, highlighting the importance of dynapenia and obesity early screening for heart disease prevention.
Collapse
|
100
|
Hu Y, Liu HX, Xu D, Xue X, Xu X. The Anti-Inflammatory Effect of miR-140-3p in BMSCs-Exosomes on Osteoarthritis. ACTA CHIRURGIAE ORTHOPAEDICAE ET TRAUMATOLOGIAE CECHOSLOVACA 2023; 90:267-276. [PMID: 37690040] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Abstract] [MESH Headings] [Subscribe] [Scholar Register] [Indexed: 09/12/2023]
Abstract
PURPOSE OF THE STUDY Articular cartilage injury is a common disease in daily life, with a high incidence. The aim of this study was to investigate the effect and mechanism of miRNA-140-3p in bone mesenchymal stem cells (BMSCs)-derived exosomes under hypoxia on inflammatory articular chondrocytes. MATERIAL AND METHODS To simulate the pathological status of arthritis, rat chondrocytes were used to establish the osteoarthritis (OA) model by IL-1β (10 μg/ml) as a modulating in vitro, and exosomes were isolated by differential ultra-high speed centrifugation. The cell counting kit-8, wound healing and flow cytometry assays were utilized to assess proliferation, migration and apoptosis of chondrocytes, respectively. Lipogenic and chondrogenic differentiation of chondrocytes were detected by oil red O staining and toluidine blue staining individually. The expressions of miR-140-3p and chondrocyte-specific gene mRNA were investigated using qRT-PCR. Western blot was applied to assess chondrocyte associated proteins and BMSC-Exo surface protein markers, and immunohistochemistry was adopted to detect the staining of collagen I and II. RESULTS Under scanning electronic microscope, the shape of exosomes was almost round. Exosome treatment prominently impaired the inhibition of chondrocytes' proliferative and migrative ability by IL-1β. It was found hypoxia had a more marked impact on proliferation, expression of collagen II and apoptosis in OA chondrocytes than normoxia, as well as a stronger effect on weakening adipose differentiation and enhancing chondrogenic differentiation in inflammatory chondrocytes. Furthermore, incubation with BMSC-Exo overexpressing miR-140-3p can remarkably increase the survival rate and migration in inflammatory chondrocytes. In addition, overexpression of miR-140-3p was found to enhance the chondrogenic differentiation of inflammatory chondrocytes. Furthermore, we found that the healing effect of exosomes on inflammatory chondrocytes under hypoxic conditions was produced by a rise in miR-140-3p expression within them and that hypoxia-mediated upregulation of miR-140-3p expression occurred through HIF-1α. CONCLUSIONS Under hypoxia, BMSC-Exo enhanced the chondrogenic phenotype, increased the viability of inflammatory chondrocytes. The overexpression of miR-140-3p in BMSC-Exo is beneficial to protect joints and delaying the pathogenesis in OA. Key words: HIF-1α, apoptosis, lipogenic differentiation, chondrogenic differentiation.
Collapse
|